2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Saturday, May 2, 2020

4:15PM-5:15PM: Abstract Number: 181

Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 146

Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial

Poster Session 3

4:15PM-5:15PM: Abstract Number: 143

Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease

Poster Session 3

4:15PM-5:15PM: Abstract Number: 161

Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States

Poster Session 3

4:15PM-5:15PM: Abstract Number: 189

Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic

Poster Session 3

4:15PM-5:15PM: Abstract Number: 180

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic

Poster Session 3

4:15PM-5:15PM: Abstract Number: 159

Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 123

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 167

Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment

Poster Session 3

4:15PM-5:15PM: Abstract Number: 118

Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers

Poster Session 3

4:15PM-5:15PM: Abstract Number: 137

Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

Poster Session 3

4:15PM-5:15PM: Abstract Number: 162

Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)

Poster Session 3

4:15PM-5:15PM: Abstract Number: 114

Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination

Poster Session 3

4:15PM-5:15PM: Abstract Number: 182

Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood

Poster Session 3

4:15PM-5:15PM: Abstract Number: 179

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network

Poster Session 3

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].